Preliminary study on the prediction of chemotherapeutic efficacy in patients with advanced digestive cancer with CD+3CD28+T cell value
- VernacularTitle:CD+3CD+28T细胞预测晚期消化道癌化疗疗效的初步研究
- Author:
Lin HAN
;
Yi PEI
- Publication Type:Journal Article
- Keywords:
Digestive system neoplasms;
T-lymphocytes;
Drug therapy;
Treatment outcome
- From:
Cancer Research and Clinic
2008;20(7):460-461,464
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between CD+3CD28+T cell value and chemotherapeutic efficacy in patients with advanced digestive cancer. Methods 38 digestive cancer patients with distant metastatic lesion were included.10 healthy persons were as control group. The absolute counts of CD+3CD28+T cell were measured with flow eytometry in these patients before chemotherapy. All patients received chemotherapy, gastric cancer: DCF regimen (docetaxel plus tegafur and cisplatin, one cycle), colorectal cancer:. Folfox regimen (L-OHP plus tegafur, two cycles), esophageal cancer: mitomycin plus tegafur and cisplatin (two cycles), gallbladder or pancreatic cancer: gemzar plus tegafur and cisplatin (one cycle). According to WHO standard, the chemotherapeutic efficacy was determined, 38 patients were divided into three groups: CR+PR (complete remission plus partial remission), SD (stable of disease) and PD (progress of disease) group. Statistical analysis was used upon all data. Results There was no significant difference in value of CD+3CD28+ T cell between CR+PR group and control group (P=0.549). The value of CD+3CD28+ T cell in SD group and PD group were significantly decreased (P=0.002, P=0.000). The value of CD+3CD28+T cell in CR+PR group was more than that in PD group (P =0.001), while in SD group was more than in PD group (P = 0.044). Conclusion The efficacy is poor, if the value of CD+3CD28+ T cell in patients with advanced digestive cancer is less than that of in healthy persons in peripheral blood. Therefore, the value of CD+3CD28+ T cell is important for the early prediction of the efficacy before chemotherapy.
